GlassScriptPhysician profile
Laura M Lambert
NPI 1639546443
$1,970.35
in general payments reported to CMS, 2019-2025
23 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $744 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.52 |
| Education | $168.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $411.49 | 2024-2025 | Krystexxa, Otezla, Evenity |
| Abbvie INC. | $297.43 | 2024-2025 | |
| Janssen Biotech, INC. | $247.59 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $220.81 | 2024-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $166.79 | 2024-2025 | |
| Pfizer INC. | $97.62 | 2024-2025 | |
| Glaxosmithkline, LLC. | $60.41 | 2024 | Benlysta |
| Octapharma USA, INC. | $59.26 | 2024-2025 | Octagam Immune Globulin (Human) |
| Grifols USA, LLC | $52.66 | 2025 | Gamunex-C |
| Fresenius Kabi USA, LLC | $52.05 | 2024-2025 | Idacio |
| Bioventus LLC | $36.96 | 2025 | Gelsyn-3 |
| Ani Pharmaceuticals, INC. | $34.46 | 2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $27.81 | 2025 | Tremfya |
| Scilex Pharmaceuticals INC. | $23.86 | 2024 | |
| Sanofi Pasteur INC. | $22.24 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $21.86 | 2025 | Zilretta |
| Kedrion Biopharma, INC. | $21.13 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Organon LLC | $20.75 | 2025 | Renflexis, Hadlima |
| Tersera Therapeutics LLC | $20.07 | 2024 | Quzyttir |
| Ucb, INC. | $18.98 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Lundbeck LLC | $18.83 | 2024 | Vyepti |
| Sobi, INC | $18.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.